Cerecin

Cerecin is a Singapore-based biotechnology company that develops therapeutics targeting the metabolic aspects of neurological diseases, including Alzheimer's, migraine, and infantile spasms. The organization focuses on ketogenic drug development, utilizing its lead compound, tricaprilin, to provide ketone bodies as an alternative brain energy substrate to improve neuro-metabolism. Transitioning from medical foods to pharmaceutical drug development, the enterprise serves patients across the United States, Canada, Korea, Singapore, and Australia. In 2023, the firm initiated its Phase 3 ALTER-AD clinical trial for Alzheimer's disease, involving patient recruitment across approximately 100 global sites. Cerecin has raised $40 million in Series II and IIA financing, backed by strategic partners and investors including Nestlé, Wilmar, and Inventages. Originally operating as Accera before relocating its headquarters from the United States to Asia in 2018, the company was founded in 2000.